nach oben

Endocrine

Erschienen in:

01.06.2010 | Original Article

Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers

verfasst von: M. Erdogan, S. Solmaz, A. Canataroglu, M. Kulaksızoglu, S. Cetinkalp, A. G. Ozgen, F. Saygili, C. Yilmaz

Erschienen in: Endocrine | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Plasma TAFI may participate in arterial thrombosis in cardiovascular diseases (CVD) and may be involved in the mechanism of vascular endothelial damage in diabetic patients. The aim of this study was to investigate the association of plasma TAFI antigen level in the development of diabetic foot ulcer in Type 2 diabetes. The TAFI antigen levels were determined in 50 patients with diabetic foot ulcers and 34 patients without diabetic foot ulcers and 25 healthy individuals. We measured TAFIa/ai antigen in plasma samples with a commercially available ELISA Kit. Diabetic foot ulcer group and diabetic group were similar in terms of mean age and sex distribution. Diabetes duration, retinopathy, neuropathy, macrovascular disease and infection were related to diabetic foot ulcers. HbA1c, HDL-cholesterol and Folic Acid levels were decreased in the diabetic foot ulcer group. TAFI levels were 99.44 ± 55.94% in control group, 135.21 ± 61.05% in diabetic foot ulcer group, 136.75 ± 59.38% in diabetic group and was statistically different (P < 0.05). But no difference was seen in TAFI levels between the diabetic foot ulcer group and diabetic group (P > 0.05). No significant difference in plasma TAFI levels were seen between diabetic foot ulcer stages. TAFI antigen levels are increased in Type 2 diabetic patients, but are not related to diabetic foot ulcer development.

J.L. Richard, S. Schuldiner, Epidemiology of diabetic foot problems. Rev. Med. Interne 29(Suppl 2), S222–S230 (2008)CrossRefPubMed

D. Malgrange, Physiopathology of the diabetic foot. Rev. Med. Interne 29(Suppl 2), S231–S237 (2008)CrossRefPubMed

C. Figueroa-Romero, M. Sadidi, E.L. Feldman, Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev. Endocr. Metab. Disord. 9(4), 301–314 (2008)CrossRefPubMed

J. Martini, Diabetic foot: detection and prevention. Rev. Med. Interne 29(Suppl 2), S260–S263 (2008)CrossRefPubMed

I. Got, Peripheral vascular disease and diabetic foot. Rev. Med. Interne 29(Suppl 2), S249–S259 (2008)CrossRefPubMed

Bader MS. Diabetic foot infection. Am. Fam. Phys. 78(1):71–79 (2008) (review)

E. Senneville, Infection and diabetic foot. Rev. Med. Interne 29(Suppl 2), S243–S248 (2008)CrossRefPubMed

D.L. Eaton, B.E. Malloy, S.P. Tsai, Isolation, molecular cloning, partial characterization of a novel carboxypeptidase B from human plasma. J Biochem Chem 266, 21833–21838 (1991)

L. Bajzar, R. Manuel, M.E. Nesheim, Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 270, 14477 (1995)CrossRefPubMed

10.

L. Bajzar, M.E. Nesheim, P.B. Tracy, The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI dependent. Blood 88, 2093–2100 (1996)PubMed

11.

C. Erem, A. Hacihasanoglu, S. Celik, E. Ovali, H.O. Ersoz, K. Ukinc, O. Deger, M. Telatar, Coagulation and fibrinolysis parameters in Type 2 diabetic patients with and without diabetic vascular complications. Med. Princ. Pract. 14, 22–30 (2005)CrossRefPubMed

12.

Y.T. Kruszynska, J.G. Yu, J.M. Olefsky, B.E. Sobel, Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 49, 633–639 (2000)CrossRefPubMed

13.

A. Hamsten, U. de Faire, G. Walldius, G. Dahlén, A. Szamosi, C. Landou, M. Blombäck, B. Wiman, Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 8549, 3–9 (1987)CrossRef

14.

Y. Hori, E.C. Gabazza, Y. Yano, A. Katsuki, K. Suzuki, Y. Adachi, Y. Sumida, Insulin resistance is associated with increased circulating levels of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients, J. Clin. Endocrinol. Metab. 87, 660–665 (2002)CrossRef

15.

H. Aubert, C. Frere, M.F. Aillaud, P.E. Morange, I. Juhan-Vague, M.C. Alessi, Weak and nonindependent association between plasma TAFI antigen levels and the insulin resistance syndrome. J. Thromb. Haemost. 1, 791–797 (2003)CrossRefPubMed

16.

A.I. Adler, E.J. Boyko, J.H. Ahroni, D.G. Smith, Lower-extremity amputation in diabetes. the ındependent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers. Diabetes Care 22, 1029–1035 (1999)CrossRefPubMed

17.

S.O. Oyibo, E.B. Jude, I. Tarawneh, H.C. Nquyen, L.B. Harkless et al., A comparison of two diabetic foot ulcer classification systems: the Wagner and the University of Texas wound classification systems. Diabetes Care 24, 84–88 (2001)CrossRefPubMed

18.

L. Prompers, M. Huijberts, J. Apelqvist, E. Jude et al., High prevalence of ischemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Diabetologia 50, 18–25 (2007)CrossRefPubMed

19.

K.C. Tan, W.S. Chow, V.H. Ai, Y.L. Siow et al., Hyperhomocysteinemia and Impaired vasomotor Function in Type 2 diabetes mellitus. Eur. J. Clin. Investig. 32, 328–334 (2002)CrossRef

20.

M. Buysscheart, J. Jamart, A.S. Dramais, P. Wallemacq et al., Micro- and macrovascular complications and hyperhomocysteinemia in Type 1 diabetic patients. Diabetes Metab. 27, 655–659 (2001)

21.

S.R. Kravitz, J. McGuire, S.D. Shanahan, Physical assessment of the diabetic foot. Adv. Skin Wound Care 16, 68–77 (2003)CrossRefPubMed

22.

W. Wang, M.B. Boffa, L. Bajzar et al., A study of the mechanism of inhibition of fibrinolysis by activated thrombinactivatable fibrinolysis inhibitor. J Biol Chem 273, 27176–27181 (1998)CrossRefPubMed

23.

Bentley J, Foster A. Multidisciplinary management of the diabetic foot ulcer. Br. J. Commun. Nurs. 12(12):S6, S8, S10 passim (2007)

24.

M.P. Khanolkar, S.C. Bain, J.W. Stephens, The diabetic foot. QJM 101(9), 685–695 (2008). Epub 2008 Mar 18CrossRefPubMed

25.

Al-Maskari F, El-Sadig M. Prevalence of risk factors for diabetic foot complications. BMC Fam. Pract. 8:59 (2007)

26.

R. Gary Sibbald, K.Y. Woo, The biology of chronic foot ulcers in persons with diabetes. Diabetes Metab. Res. Rev. 24(Suppl 1), S25–S30 (2008)CrossRefPubMed

27.

P.C. Leung, Diabetic foot ulcers—a comprehensive review. Surgeon 5(4), 219–231 (2007). reviewCrossRefPubMed

28.

C.A. Andersen, T.S. Roukis, The diabetic foot. Surg. Clin. North Am. 87(5), 1149–1177 (2007)CrossRefPubMed

29.

H.M. Rathur, A.J.M. Boulton, The diabetic foot. Clin. Dermatol. 25, 109–120 (2007)CrossRefPubMed

30.

G.W. Gibbons, The diabetic foot, in Principles and Practice of Endocrinology and Metabolism, ed. by K.L.Becker, 3rd edn. (A Walter Kluwer Company, Philadelphia, 2001), pp. 1435–1438

31.

N. Papanas, E. Maltezos, Advances in treating the ischaemic diabetic foot. Curr. Vasc. Pharmacol. 6(1), 23–28 (2008)CrossRefPubMed

32.

A. Santamaria, A. Oliver, M. Borrell, J. Mateo, R. Belvis, J. Marti-Fabregas, R. Ortin, I. Tirado, J.C. Souto, J. Fontcuberta, Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 34(10), 2387–2391 (2003)CrossRefPubMed

33.

F.W. Leebeek, M.P. Goor, A.H. Guimaraes, G.J. Brouwers, M.P. Maat, D.W. Dippel, D.C. Rijken, High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J. Thromb. Haemost. 3(10), 2211–2218 (2005)CrossRefPubMed

34.

A. Santamaria, A. Martinez-Rubio, M. Borrell et al., Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica 89(7), 880–881 (2004)PubMed

35.

P. Lisowski, J. Malyszko, T. Hirnle et al., Thrombin activatable fibrinolysis inhibitor (TAFI) in stable angina pectoris patients undergoing coronary artery bypasses grafting (CABG). Rocz. Akad. Med. Bialymst. 50, 166–172 (2005)PubMed

36.

D. Tschoepe, The activated megakaryocyte-platelet-system in vascular disease: focus on diabetes. Semin. Thromb. Hemost. 21(2), 152–160 (1995)CrossRefPubMed

37.

J. Małyszko, J.S. Małyszko, T. Hryszko, M. Myśliwiec, Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy. Thromb. Haemost. 91(3), 480–486 (2004)PubMed

38.

Y. Yano, N. Kitagawa, E.C. Gabazza, K. Morioka, H. Urakawa, T. Tanaka, A. Katsuki, R. Araki-Sasaki, Y. Hori, K. Nakatani, O. Taguchi, Y. Sumida, Y. Adachi, Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J. Clin. Endocrinol. Metab. 88(2), 736–741 (2003)CrossRefPubMed

Titel: Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers
verfasst von: M. Erdogan
S. Solmaz
A. Canataroglu
M. Kulaksızoglu
S. Cetinkalp
A. G. Ozgen
F. Saygili
C. Yilmaz
Publikationsdatum: 01.06.2010
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2010
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-010-9329-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

Blutdrucksenkung könnte Uterusmyome verhindern

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Update Innere Medizin

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Maternal diabetes increases apoptosis in mice oocytes, not 2-cell embryos

Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus

Preliminary biochemical characterization of the novel, non-AT1, non-AT2 angiotensin binding site from the rat brain

Analysis of angiotensin II- and ACTH-driven mineralocorticoid functions and omental adiposity in a non-genetic, hyperadipose female rat phenotype

−607 C/A polymorphism in the promoter of IL-18 gene is associated with 2 h post-loading plasma glucose level in Chinese

Monocyte chemoattractant protein-1 (MCP-1) 2518G/A gene polymorphism in Turkish type 2 diabetes patients with nephropathy

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

Blutdrucksenkung könnte Uterusmyome verhindern

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Update Innere Medizin